Morepen Labs
Stock Snapshot
Price Performance
Vista Outlook
Basis of our Recommendation
Morepen Laboratories is strategically transitioning from a traditional API manufacturer to a CDMO model, focusing on high-value molecules and complex therapies. Management's emphasis on operational efficiency and R&D enhancement aligns with Vista's forecast of recovering revenue growth and improving margins. The company's strong export performance, bolstered by favorable currency dynamics, supports its revenue outlook, while the planned restructuring, including the slump sale of its medical device division, aims to streamline operations and enhance focus on core competencies. However, challenges such as rising input costs and global pricing reforms could pressure margins. Overall, Vista anticipates a 31.96% upside, with a 12-month target price of approximately 150.09, reflecting confidence in Morepen's ability to navigate its transformation successfully. Over the next 12-24 months, key opportunities include the expansion of its CDMO capabilities and the introduction of innovative products, while watchpoints include the execution of its strategic initiatives and external market pressures
Why We Like This Stock
- Transition to a CDMO model enhances growth potential through high-value molecule development
- Strong export performance supported by favorable currency dynamics is expected to uplift revenues
- Management's focus on operational efficiency and R&D is likely to improve margins and profitability
Things To Watch Out For
- Rising input costs may exert pressure on profit margins
- Global pricing reforms and regulatory uncertainties could impact revenue stability
- Increased competition in the biosimilars space may affect profitability and market share
Key Parameters
Financial Snapshot
View Technicals Analysis →| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 1,690 | 1,812 | 1,806 | 2,147 | 2,501 |
| Profit Before Tax (Cr.) | 135 | 155 | 94 | 171 | 182 |
| PBT Margin | 8.0% | 8.6% | 5.2% | 8.0% | 7.3% |
| Net Profit (Cr.) | 96 | 123 | 83 | 148 | 156 |
| Earnings Per Share | 1.8 | 2.2 | 1.5 | 2.7 | 2.8 |
Analyst Recommendations
No analyst recommendations available.
Company Overview
Show Company Profile
Morepen Laboratories Limited develops, manufactures, markets, and sells active pharmaceutical ingredients (APIs), branded and generic formulations, and home health products in India, the United States, and internationally. The company offers APIs for anti-histaminic, anti-asthmatic, anti-lipemic, anti-hypertensive, anti-diabetic, anti-coagulant, anti-ulcerative, and anti-depressant drugs; and home diagnostic products, such as air purifiers, sphygmomanometers, blood glucose test strips, blood pressure monitors, breathe free vaporizers, stethoscopes, digital thermometers, blood glucose monitors, nebulizers, heat belts, and pulse oximeters. It also provides OTC and healthcare products, including fever X for fever; Pain X for pain; Fiber-X for constipation; sat isabgol; Acidity X for acidity; Burnol, a first degree/minor burns cream; and formulations for nutrition and probiotics, gastroenterology, antibiotics, gynecology, anti-allergic, and central nervous system, as well as cardiology, diabetology, and nutraceuticals. The company offers over the counter products under the Dr. Morepen brand name. Morepen Laboratories Limited was incorporated in 1984 and is based in Gurugram, India.